Letrozole CYP19A1 Aromatase Inhibitor Research: Endocrine Cell Model Studies
The content, articles and product information provided on this website are strictly educational and informational. They are intended to be used for in vitro research only. “In vitro” is a Latin phrase, “in glass,” that refers to research that is conducted outside of a living organism. Note, these products are not pharmaceuticals or medicines and have not been approved by the FDA for the diagnosis, treatment or prevention of any illnesses or disorders. These products are legally prohibited from human or animal consumption.
Overview of Letrozole Pharmacology
Letrozole (MW 285.30 g/mol, CAS 112809-51-5) is a non-steroidal triazole competitive aromatase (CYP19A1) inhibitor with subnanomolar Ki values at the enzyme active site. This third-generation aromatase inhibitor demonstrates exceptional selectivity and potency in CYP19A1 enzyme kinetics assay systems. Research applications encompass endocrine cell model studies for characterisation of aromatase inhibition mechanisms, selectivity profiles, and steroidogenesis pathway modulation.
The triazole pharmacophore of letrozole coordinates with the heme iron of CYP19A1, forming a reversible enzyme-inhibitor complex that blocks androgen-to-estrogen conversion. In vitro research demonstrates letrozole's superior binding affinity compared to first-generation aromatase inhibitors, with IC50 values in the low nanomolar range across multiple cell-based assay systems.
CYP19A1 Enzyme Kinetics Research
Letrozole CYP19A1 inhibition is characterised using microsomal preparations from CYP19A1-expressing JEG-3 (placental), H295R (adrenocortical), and MCF-7aro (breast) cell lines. Enzyme kinetic studies demonstrate competitive inhibition patterns with Ki values ranging from 0.1-1.4 nM depending on substrate concentration and assay conditions.
Binding Affinity Studies
Saturation binding experiments using [³H]-letrozole reveal high-affinity binding sites on CYP19A1 with Kd values of 0.8-2.1 nM. Competition binding assays demonstrate selectivity over other cytochrome P450 enzymes, with >1000-fold selectivity versus CYP17A1, CYP11B1, and CYP21A2. Scatchard analysis indicates single-site binding kinetics consistent with competitive inhibition mechanisms.
Enzyme Activity Assays
In vitro aromatase activity is measured using androstenedione-to-estrone conversion assays in cell-free microsomal systems. Letrozole demonstrates dose-dependent inhibition with IC50 values of 0.7-2.8 nM across different cell model preparations. Time-course studies reveal rapid binding kinetics with maximal inhibition achieved within 15-30 minutes of compound addition.
Cell-Based Assay Systems
H295R Adrenocortical Cell Models
H295R cells expressing endogenous CYP19A1 provide a physiologically relevant model for steroidogenesis research. Letrozole treatment results in dose-dependent reduction of estradiol production with concurrent accumulation of testosterone and androstenedione. Real-time PCR analysis demonstrates no significant effects on CYP19A1 mRNA expression, confirming enzyme-level rather than transcriptional inhibition.
JEG-3 Placental Cell Studies
JEG-3 choriocarcinoma cells constitute an established model for placental aromatase research. These cells demonstrate robust CYP19A1 expression and estrogen biosynthesis capacity. Letrozole inhibition studies in JEG-3 cells reveal complete suppression of estradiol production at concentrations ≥10 nM, with partial inhibition observed at 1-5 nM concentrations.
Transfected Cell Expression Systems
CYP19A1-transfected HEK293 and CHO cell lines enable controlled expression studies with defined enzyme levels. These systems demonstrate consistent letrozole inhibition profiles with reduced variability compared to endogenous expression models. Flow cytometry analysis confirms maintained cell viability across tested concentration ranges.
Steroidogenesis Pathway Analysis
Hormone Quantification
ELISA-based quantification of steroid hormones reveals letrozole's selective effects on the final aromatization step. While estradiol and estrone levels decrease dramatically, upstream androgens accumulate proportionally. Testosterone:estradiol ratios increase >100-fold in responsive cell models, indicating complete pathway blockade.
Metabolite Profiling
LC-MS/MS analysis of culture media identifies accumulation of 19-hydroxyandrostenedione, the immediate CYP19A1 substrate, confirming specific enzyme inhibition. No significant changes in upstream steroidogenic intermediates suggest pathway-specific effects without broader P450 system disruption.
Selectivity and Specificity Studies
Cross-reactivity screening against cytochrome P450 enzyme panels demonstrates letrozole's exceptional selectivity for CYP19A1. Inhibition constants for related enzymes exceed 10 μM, representing >1000-fold selectivity margins. Radioligand displacement assays confirm minimal interaction with steroid hormone receptors at pharmacologically relevant concentrations.
Research Summary
Letrozole represents a highly potent and selective CYP19A1 aromatase inhibitor with subnanomolar binding affinity and competitive inhibition kinetics. In vitro cell model studies demonstrate consistent enzyme inhibition across multiple expression systems, with complete suppression of estrogen biosynthesis and proportional androgen accumulation. The compound's exceptional selectivity profile and rapid binding kinetics make it an invaluable research tool for investigating aromatase function and steroidogenesis pathway regulation in endocrine cell models.
All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.
